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Abstract 
Introduction: Methoxphenidine is a novel dissociative designer drug of the 
diarylethylamine class which shares structural features with phencyclidine (PCP), and 
is not at present subject to restrictive regulations. There is very limited information 
about the acute toxicity profile of methoxphenidine and the only sources are 
anonymous internet sites and a 1989 patent of the Searle company. We report a 
case of analytically confirmed oral methoxphenidine toxicity. 
Case details: A 53-year-old man was found on the street in a somnolent and 
confusional state. Observed signs and symptoms such as tachycardia (112 bpm), 
hypertension (220/125 mmHg), echolalia, confusion, agitation, opisthotonus, 
nystagmus, and amnesia were consistent with phencyclidine-induced adverse 
effects. Temperature (99.1 °F, 37.3°C) and peripheral oxygen saturation while 
breathing room air (99%) were normal. Laboratory analysis revealed an increase of 
creatine kinase (max 865 U/L), alanine aminotransferase (72 U/L), and gamma-
glutamyl transpeptidase (123 U/L). Methoxphenidine was identified by a liquid 
chromatography tandem mass spectrometry toxicological screening method using 
turbulent flow online extraction in plasma and urine samples collected on admission. 
The clinical course was favourable and signs and symptoms resolved with 
symptomatic treatment. 
Conclusion: Based on this case report and users’ web reports, and compatible with 
the chemical structure, methoxphenidine produces effects similar to those of the 
arylcyclohexylamines, as PCP. 
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Introduction 
Methoxphenidine (MXP) or 2-MeO-diphenidine (1-[1-(2-methoxyphenyl)-2-
phenylethyl]piperidine), is a diarylethylamine compound that shares structural 
features with the arylcyclohexylamines, such as phencyclidine (PCP), ketamine, and 
methoxetamine (MXE), and with the diarylethylamine diphenidine (Figure 1).1 These 
recreational psychoactive substances with dissociative effects are highly addictive 
because of their ability to produce intense psychedelic effects.1 Shortly after the 2013 
UK ban on arylcyclohexylamines, methoxphenidine became available on the grey 
market.1 It is advertised and sold through the internet as a research chemical in form 
of a white powder or crystals. Methoxphenidine, which possesses a lower affinity for 
N-methyl-D-aspartate (NMDA) receptors than the related compound diphenidine, was 
first reported in a 1989 patent as a potential treatment for neurotoxic injury.2 As a 
consequence of structural similarity, the effects of methoxphenidine might be 
assumed to be similar to those of other dissociative drugs.1 There is no reliable 
information on the pharmacology, effects and toxicity of this substance, and 
established analytical methods are lacking. The only sources of information are drug 
users’ web discussion forums, in which euphoria, feeling of happiness, stimulating 
effects, disorientation, dissociative effects (starting at 80 mg methoxphenidine), and 
transient anterograde amnesia lasting for 3-6 h are mentioned. Some users report 
undesired effects including tachycardia, hyperthermia, panic attacks, and, after 
ingestion of higher doses, seizures requiring hospitalisation.1 Methoxphenidine is 
generally used orally, in doses of 80-150 mg (in some reports up to 500 mg), and 
users report a steep dose-response curve.3,4 Effects are described to begin after 60 
min, with a duration up to 18 h.4 We report a case of acute toxicity after oral 
methoxphenidine use confirmed by the identification of the substance and its 
metabolites in serum and urine by a liquid chromatography tandem mass 
spectrometry toxicological screening method. 
 
Case report 
A 53-year-old Caucasian male with a history of diabetes mellitus and multiple 
substance abuse, was found on the street in a somnolent and confusional state, with 
transient echolalia and unable to communicate. His current medication included 
buprenorphine as opiate substitution therapy (16 mg/day), amlodipine (5 mg/day), 
candesartan (32 mg/d) dihydrochlorothiazide (25 mg/day), metformin (2000 mg/d), 
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subcutaneous insulin, and simvastatin (40 mg/d). He carried a packet containing a 
white powder labelled “methoxphenidine”, which was later analytically confirmed by 
gas chromatography mass spectrometry (Scientific Forensic Service of Zurich) to be 
pure methoxphenidine. 
On arrival at the emergency department the patient suddenly lost consciousness, and 
developed opisthotonus, horizontal nystagmus, and conjugate eye deviation. He was 
immediately transferred to the intensive care unit, where he arrived with central 
nervous system depression and a Glasgow Coma Scale score of 10. The physical 
examination revealed hypertension (220/125 mmHg) and tachycardia (112 bpm); 
body temperature was 99.1 °F (37.3°C), respiratory rate was 14/min, and the 
peripheral oxygen saturation was 99% while breathing room air. The pupils were 
miotic, non-reactive, and horizontal nystagmus was still present. Deep tendon 
reflexes were normal and the Babinski sign was negative. The muscle tone was 
normal and there was no clonus. The general physical examination was 
unremarkable. The ECG was normal, except for mild sinus tachycardia (105 bpm) 
and mild QTc-prolongation (465 ms). There were no signs of trauma, and the CT 
scan showed neither cerebral hemorrhage nor injury of the cervical spine. Laboratory 
analysis revealed an increase of creatine kinase (max 865 U/L; reference <190 U/L), 
alanine aminotransferase (72 U/L; reference < 41 U/L), and gamma-glutamyl 
transpeptidase (123 U/L; reference < 61 U/L). Serum bilirubin and alkaline 
phosphatase as well as other parameters including blood glucose level (9.9 mmol/L, 
on admission), serum electrolytes, creatinine, INR and the complete blood count 
were normal. ELISA urine toxicology screen was positive for benzodiazepines, but 
negative for cocaine, amphetamine, tetra-hydro-cannabinol, opioids, barbiturates, 
methadone, tricyclic antidepressants, 3,4-methylenedioxymethamphetamine, and 
methamphetamines. Ethanol was not detectable in serum.  
Lorazepam (2 mg intravenously) was initially administered for treatment of 
hypertension and tachycardia, with a decrease of blood pressure and heart rate 
within 30 min to 172/90 mmHg and 103 bpm, respectively. Concomitantly, nystagmus 
and miosis resolved. The patient developed urinary retention requiring 
catheterization, and lidocaine was used as topical anaesthetic. 90 min after 
admission the patient regained consciousness, but was confused, disoriented and 
showed fumbling movements. He was progressively more agitated, and was 
therefore managed by further lorazepam administration (6 mg intravenously, 
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cumulative dose). The subsequent clinical course was uneventful and the next 
morning the patient was asymptomatic except for amnesia of the event and was 
therefore discharged home. 
 
Plasma and urine samples collected on admission were analysed by a liquid 
chromatography tandem mass spectrometry toxicological screening method using 
turbulent flow online extraction.5 The method uses a linear ion trap mass 
spectrometer to acquire MS2 and MS3 spectra in positive as well as negative mode in 
the same run. Identification of compounds is based on MS2 and MS3 spectral 
libraries. Urine samples are analysed twice, once natively and once after enzymatic 
cleavage of the glucuronide metabolites. Serum is analyzed only once. 
Methoxphenidine was added to the spectral libraries (MS2 and MS3) using pure 
reference compound that has been provided by the Scientific Forensic Service of 
Zurich. For the identification of methoxphenidine metabolites, the urine sample was 
analysed in untargeted mode with the same liquid chromatography high resolution 
mass spectrometry toxicological screening method using turbulent flow online 
extraction. 
Methoxphenidine was identified in the plasma as well as in the urine sample (Figure 
2). In the urine sample, the following methoxphenidine metabolites were identified in 
addition to the parent compound: three different hydroxylation products, the product 
of O-demethylation, and three different glucuronidated hydroxylation products. 
Furthermore, trace amounts of benzoylecgonine, amlodipine and metabolite, 
buprenorphine and metabolite, norfentanyl, hydrochlorothiazide, metformin, lidocaine 
and metabolite, as well as nicotine and metabolite were detected. In the plasma, in 
addition to methoxphenidine, lorazepam, lidocaine and metabolite, and amlodipine 
were detected. 
 
Discussion 
Dissociative drugs including PCP and ketamine are used recreationally for their mind-
altering effects. Starting with the first dissociative designer drug, 4-MeO-PCP in 2008, 
the dissociative designer drug market has rapidly evolved, and several of these 
compounds have reached widespread use internationally.1 This is true for MXE, 
which has therefore been scheduled in recent years as a controlled substance in 
many countries. Drug-selling sites now specifically promote methoxphenidine as a 
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legal replacement for the banned arylcyclohexylamines such as MXE and 4-MeO-
PCP. Methoxphenidine seems to be rapidly gaining popularity, and forum posts on 
this compound are steadily increasing. Concomitantly to the appearance of 
methoxphenidine on the grey market, diphenidine, another dissociative designer drug 
of the diarylethylamine class with a very close chemical structure and similar effects 
to methoxphenidine, emerged. As is usually the case for novel psychoactive 
substances, also for the arylcyclohexylamines and diarylethylamines, little is known 
about their health risks when they enter the recreational drug scene. 
Methoxphenidine users describe the effects as similar to those of ketamine and 
MXE.6,3 Actually, signs and symptoms observed in our patient such as hypertension, 
tachycardia, confusion, sedation, shifts in perception of reality, agitation, nystagmus, 
opisthotonus, amnesia, and urinary retention are compatible with the effects induced 
by MXE, ketamine, and PCP.7,8,9  Moreover, speech disorders such as pressured 
speech, verbigerations, and echolalia have been regularly reported by users of PCP 
and ketamine.8,9 
Hypertension and nystagmus, which were observed in our patient, are hallmarks of 
PCP intoxication, and both have been reported to occur in about 57% of the cases 
and to resolve within 4 h of PCP consumption.9 Also miosis is common in PCP 
intoxication12 and was observed in our patient. A major contribution by buprenorphine 
seems unlikely as the patient had no respiratory depression and showed a rapid 
resolution of the central nervous system depression. 
The initial neurological presentation of our patient with loss of consciousness 
associated with opisthotonus is compatible with a tonic seizure. Seizures have been 
reported after use of PCP9 and also rarely by MXP users.1,3 Furthermore, the 
analgesic drug lefetamine, which is structurally related to methoxphenidine and which 
was abused in Japan and Europe and has been withdrawn from the market, has 
been reported to cause seizures in rats.10 
In our patient, all detected substances other than methoxphenidine, norfentanyl, and 
benzylecgonine (i.e. buprenorphine, amlodipine, candesartan, dihydrochlorothiazide, 
metformin, lorazepam, and lidocaine) were used therapeutically. Norfentanyl and 
traces of benzoylecgonine slightly above the detection limit in absence of the parent 
compounds were found in the urine sample only, and this is compatible with the 
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prolonged detectability (up to 72 hours) of norfentanyl, the major metabolite of 
fentanyl,11 and benzoylecgonine.12 We are therefore persuaded that there is enough 
evidence to reject the hypothesis of a simultaneous abuse of fentanyl and/or cocaine, 
which could have influenced the clinical course. 
 
Because methoxphenidine is at present not subject to restrictive regulations, it seems 
plausible that the consumption of this substance might increase internationally. For 
this reason, further studies are needed to determine the pharmacological and 
toxicological properties of methoxphenidine, and to analyse patterns of acute toxicity 
in humans and possible long-term effects, including neuropsychiatric disorders as 
well as urinary bladder, liver, and brain injury, which were observed after long-term 
abuse of PCP and ketamine.13,14,15 
 
In conclusion, methoxphenidine appears to have a similar acute toxicity profile to 
other arylcyclohexylamines, such as PCP, ketamine, and MXE. On the basis of the 
very limited evidence available, management of patients presenting with acute 
toxicity related to methoxphenidine use should be as for other dissociative drugs. 
 
Patient’s consent 
A document showing the patient’s written consent to this publication is available on 
request. 
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